Latest news with #VagusNerveStimulation
News18
4 days ago
- Entertainment
- News18
What Is Epilepsy, Which Shefali Jariwala Battled For 15 Years? Symptoms, Causes And Treatment
Last Updated: Kaanta Laga's success catapulted Shefali Jariwala to overnight stardom in 2002. However, she had revealed she had been suffering from epilepsy since the age of 15. Shefali Jariwala Death: Actress and reality show star Shefali Jariwala, best know for her iconic appearance in the ' Kaanta Laga' music video and her participation in Bigg Boss 13, has passed away reportedly due to cardiac arrest. Her sudden demise has sent shockwaves through the television industry and left her fans heartbroken. The actor, who died on Friday aged 42, was meant to be the next big thing in showbiz, but a secret illness derailed that promising career. Amid the heartbreaking news, a throwback interview of the Bollywood star has resurfaced, where she opened up about her health struggles and why she stepped back from her career. Kaanta Laga's success catapulted Jariwala to overnight stardom in 2002. However, in an interview with The Times of India, Jariwala had revealed she had been suffering from epilepsy since the age of 15. 'I had an epilepsy seizure at the age of 15. I remember at that time I was under tremendous pressure to do well in my studies. Stress and anxiety can lead to seizures. It's interrelated, you could get a seizure due to depression and vice versa," she had shared. What Is Epilepsy? Epilepsy is a severe neurological condition that can have a significant impact on an individual's daily life. If left untreated or poorly managed, it can lead to life-threatening complications. However, with appropriate medical intervention and proper precautions, individuals living with epilepsy can manage the condition and avoid severe outcomes. According to Doctor Vishwanathan Iyer, a neurosurgeon at Zynova Shalby Hospital in Mumbai, Epilepsy is a neurological disorder that causes abnormal electrical activity in the brain, leading to seizures. The severity and frequency of these seizures can vary widely among individuals, depending on the extent of the condition. While epilepsy can develop at any age, it is most commonly diagnosed during childhood. Living with epilepsy can be a daunting and stressful experience. Those affected may find themselves relying on others for basic activities like driving, eating, bathing, or dressing, which can lead to feelings of frustration, anger, anxiety, and even depression. Precautions And Treatment In an interview with HT Lifestyle, Dr Iyer emphasised the importance of both medical treatment and preventive measures to save lives and manage the condition. Medication is often the first line of defence, as it helps stabilise brain activity and reduce the frequency of seizures. In cases where medications are ineffective, surgical options may be considered. For more severe instances, treatments like Vagus Nerve Stimulation (VNS) or Responsive Neurostimulation (RNS) can be recommended for patients who do not respond to conventional medications. He also recommended making significant lifestyle changes to improve overall well-being and manage the condition effectively. Simple but essential practices such as getting 7 to 8 hours of sleep every night, managing stress through relaxation techniques, avoiding known seizure triggers, and maintaining a balanced diet can greatly help in controlling epilepsy. Who Was Shefali Jariwala? Shefali first rose to fame in the early 2000s with her bold and glamorous look in the remix music video Kaanta Laga, which became an overnight sensation. She was dubbed 'The Kaanta Laga Girl" and was seen as a trailblazer for the remix era. She also made a brief appearance in the 2004 film Mujhse Shaadi Karogi starring Salman Khan and Akshay Kumar. In later years, Shefali transitioned to reality TV and gained popularity through her participation in Nach Baliye with her husband, and later, Bigg Boss 13. Her entry into the Bigg Boss house was particularly talked-about due to her history with fellow contestant and late actor Sidharth Shukla. The two had dated over a decade ago, but Shefali maintained that they were always respectful of each other on and off the show. Location : Mumbai, India, India First Published: June 28, 2025, 12:19 IST News lifestyle What Is Epilepsy, Which Shefali Jariwala Battled For 15 Years? Symptoms, Causes And Treatment
Yahoo
22-05-2025
- Health
- Yahoo
UT Dallas breakthrough medical study could revolutionize spinal cord recovery
The Brief Researchers at UT Dallas have miniaturized an implantable device for spinal cord injury recovery. Paired with physical therapy, the device has shown significant improvement, with potential even for patients injured decades ago. The breakthrough challenges long-held medical beliefs, offering new hope for those with chronic spinal cord injuries to their neck. DALLAS - Researchers at UT Dallas say they've made a historic breakthrough in spinal cord injury recovery with a recent implant study. According to a Nature paper released on Wednesday by the researchers, a minuscule new implantable device paired with physical therapy has achieved significant recovery in clinical trial patients, including one 45 years post-injury. The groundbreaking technology is the next generation of Vagus Nerve Stimuli (VNS), which the UT Dallas Nature study says is 50 times smaller than traditional devices. The tiny implantable device, pictured below sitting on a penny, is used for a neurorehabilitation process called "Closed-Loop Vagus Nerve Stimulation," or CLV. The first in-human study of the treatment took place in North Texas. The researchers say their new VNS, when used in tandem with targeted physical therapy, led to significant recovery of hand and arm function in people with chronic spinal cord injuries in their neck. One participant included in the study sustained their injury over 45 years ago, they say. Participants in the study who received the miniaturized VNS were reportedly found to have a dose-dependent improvement in their recovery, meaning the more therapy given, the better. In addition, the researchers have found no ceiling to the recovery potential. The paper says clinical measures in the trial also improved identically to real-world function for the participants. Why you should care According to a Wednesday release from Dr. Jane G. Wigginton, emergency medicine physician and Chief Medical Officer for the Texas Biomedical Device Center at the University of Texas at Dallas, the discoveries laid out in the new paper challenge long-held medical beliefs. Wigginton says the study's findings show that recovery is possible for spinal cord injury patients even decades after losing motor function; a discovery that defies "medical dogma." Wigginton notes the North Texas achievement is a scientific success and a beacon of hope for patients all over the world. What they're saying "We're not just seeing gains on clinical tests — we're seeing patients fasten their own necklaces, zip jackets in seconds instead of minutes, and throw balls for their dogs again. These are the moments that change lives," Wigginton said. The Source Information in this article came from a UT Dallas Nature paper and UT Dallas' Dr. Jane Wigginton.
Time of India
13-05-2025
- Health
- Time of India
Teen with cerebral palsy undergoes rare epilepsy op
Kolkata: A boy with cerebral palsy , Minhaz Hussain (15), who suffered recurrent bouts of seizures for years, underwent a rare surgery at CMRI, the third such procedure in the eastern region. Earlier anti-epilepsy therapy failed to better his state, but Vagus Nerve Stimulation had lowered seizure frequencies, said a doctor. Consultant neurosurgeon Rathijit Mitra and his team conducted the procedure. "We implanted an electrode on the left vagus nerve in the neck and linked it to a pulse generator, placed under the skin near the collarbone. It sends electrical impulses to the brain to help control seizures," said Mitra. The earlier VNS cases were held at INK. —Sumati Yengkhom
Yahoo
13-05-2025
- Business
- Yahoo
Tivic Expands VNS Intellectual Property Portfolio
- New patent protects methods for increasing efficacy via personalization of stimulation parameters and electrode positioning - FREMONT, Calif., May 13, 2025--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today it is expanding its non-invasive VNS patent portfolio with the filing of a new patent application with the United States Patent and Trademark Office. Patent No. 63,801,058 entitled "Vagus Nerve Stimulation System" expands the claims and protection around the technology that Tivic is developing and which it expects will redefine state-of-the art in non-invasive vagus nerve stimulation. "We continue to build a defensible position for our next generation VNS technology," said Blake Gurfein, Tivic Chief Scientific Officer. "This patent protects key learnings from our VNS optimization study, which is advancing the science of vagus nerve interventions. In fact, we believe we are moving the needle on what will become the state-of-the art treatment approach by delivering much greater and more consistent therapeutic effects compared to what is currently available." Jennifer Ernst, Tivic CEO, stated, "As we continue to advance our VNS program, protecting our proprietary and intellectual property is critical. Tivic's diversified portfolio of bioelectronic VNS and biologic immunotherapies represent a unique breadth of treatments to address health issues where immune system dysregulation is a significant underlying factor." About Tivic Health Systems, Inc. Tivic Health is a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health. Tivic Health's bioelectronic program is developing non-invasive medical devices that personalize key stimulation for the vagus nerve to deliver meaningful improvements in clinically relevant measures of the autonomous nervous system compared to current treatments, which are often invasive, ineffective or both. The company's lead biopharma product candidate, the TLR5 agonist Entolimod™ to treat ARS, has been granted Fast Track and Orphan Drug designation by the FDA. Tivic Health's first FDA approved product ClearUP™ is proven to treat sinus pain and pressure, and is available through online retailers and commercial distributors. For more information about Tivic Health, visit: Forward-Looking Statements This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: statements regarding the future development of ncVNS treatment, the Tivic Health's ability to commercialize products arising out of the ncVNS treatment and the Tivic Health's plans to seek regulatory approval for such clinical products and Tivic Health's continued focus on developing ncVNS treatment, including in the epilepsy, post-traumatic stress disorder, and/or ischemic stroke space; expected clinical utility including which patient populations may be pursued; market and other conditions; supply chain constraints; macroeconomic factors, including inflation; and unexpected costs, charges or expenses that reduce Tivic Health's capital resources. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Tivic Health's actual results to differ from those contained in the forward-looking statements, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, under the heading "Risk Factors"; as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law. View source version on Contacts Investor Contact: Hanover International, Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
13-05-2025
- Business
- Business Wire
Tivic Expands VNS Intellectual Property Portfolio
FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health ® Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, announced today it is expanding its non-invasive VNS patent portfolio with the filing of a new patent application with the United States Patent and Trademark Office. Patent No. 63,801,058 entitled ' Vagus Nerve Stimulation System ' expands the claims and protection around the technology that Tivic is developing and which it expects will redefine state-of-the art in non-invasive vagus nerve stimulation. 'We continue to build a defensible position for our next generation VNS technology,' said Blake Gurfein, Tivic Chief Scientific Officer. 'This patent protects key learnings from our VNS optimization study, which is advancing the science of vagus nerve interventions. In fact, we believe we are moving the needle on what will become the state-of-the art treatment approach by delivering much greater and more consistent therapeutic effects compared to what is currently available.' Jennifer Ernst, Tivic CEO, stated, 'As we continue to advance our VNS program, protecting our proprietary and intellectual property is critical. Tivic's diversified portfolio of bioelectronic VNS and biologic immunotherapies represent a unique breadth of treatments to address health issues where immune system dysregulation is a significant underlying factor.' About Tivic Health Systems, Inc. Tivic Health is a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health. Tivic Health's bioelectronic program is developing non-invasive medical devices that personalize key stimulation for the vagus nerve to deliver meaningful improvements in clinically relevant measures of the autonomous nervous system compared to current treatments, which are often invasive, ineffective or both. The company's lead biopharma product candidate, the TLR5 agonist Entolimod™ to treat ARS, has been granted Fast Track and Orphan Drug designation by the FDA. Tivic Health's first FDA approved product ClearUP™ is proven to treat sinus pain and pressure, and is available through online retailers and commercial distributors. For more information about Tivic Health, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: statements regarding the future development of ncVNS treatment, the Tivic Health's ability to commercialize products arising out of the ncVNS treatment and the Tivic Health's plans to seek regulatory approval for such clinical products and Tivic Health's continued focus on developing ncVNS treatment, including in the epilepsy, post-traumatic stress disorder, and/or ischemic stroke space; expected clinical utility including which patient populations may be pursued; market and other conditions; supply chain constraints; macroeconomic factors, including inflation; and unexpected costs, charges or expenses that reduce Tivic Health's capital resources. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Tivic Health's actual results to differ from those contained in the forward-looking statements, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, under the heading 'Risk Factors'; as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
